Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide in Anti-MAG Neuropathy: Phase 1b Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* • Patients must have an Anti-Myelin Associated Glycoprotein titer~  * Patients must have Distal acquired demyelinating sensorimotor (DADS) peripheral neuropathy phenotype as defined per European Federation of Neurological Societies (EFNS) demyelinating criteria with preferential distal nerve involvement, as captured per terminal latency index \[terminal distance/(conduction velocity x terminal latency)\], in the setting of a monoclonal gammopathy~ * Patients must be at least 18 years of age with no evidence of multiple myeloma, light chain amyloidosis or other hematologic disorder requiring treatment.~ * Patient may be enrolled at any time from last line of therapy.~ * Patients must have ANC \> 1000/µL and Platelets ≥75,000/µL~ * Patients must have adequate hepatic function as evidenced by: total bilirubin \< 1.5 mg/dL, alkaline phosphatase \< 3X the ULN, and AST/ALT \< 2X the ULN.~ * Patients must be able to take any of the following once lenalidomide starts and for at least 5 days after last dose lenalidomide: 1) 81-325 mg of coated aspirin daily; 2) full dose warfarin (target INR 2-3); 3) 2.5 mg or above of apixaban twice daily; 4) low molecular weight heparin; 5) 20 mg or above of rivaroxaban daily.~ * Patients must have adequate renal function as evidenced by serum creatinine \< 2mg/dL or calculated creatinine clearance of ≥ 40ml/min within 14 days of registration using MDRD formula.~ * Patient must be able to swallow capsule or tablet.~ * Patients must provide informed consent.~ * All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program.~ * Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.~ * Two negative pregnancy tests will be required for all women of child bearing potential, with the second negative test having been at least 7 days prior to starting the study drug. Breast feeding is not permitted.~ * Fertility requirements~    * Female patients with child bearing potential must have two negative pregnancy tests, with the second negative test having been at least 7 days prior to starting the study drug.~   * Male patients must agree to use an adequate method of contraception starting from screening to 90 days after stopping the drug.~   * Female patients must be either posy-menopausal, free from menses ≥2 yrs., surgically sterilized, willing to use two adequate barrier methods of contraception to prevent pregnancy, or agree to abstain from sexual activity starting from screening to 90 days after stopping the drug.~   * Female patients of child bearing potential must agree to comply with the fertility and pregnancy test requirements dictated by the Rev-Assist program.~Exclusion Criteria:~* • Patient with concurrent hematologic or oncologic malignancy requiring systemic treatment~  * History of allergic reaction (including erythema nodosum) to lenalidomide~ * Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from the side-effects of surgery~ * Patients with a history of gastrointestinal surgery or other procedure that might, in the opinion of the investigator(s), interfere with the absorption or swallowing of the study drugs.~ * Patients with any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to them by the study staff.~ * Any other medical condition, including mental illness or substance abuse deemed by the investigator(s) to likely interfere with the patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide escalation and expansion (Type: EXPERIMENTAL): Among the participants who will be receiving lenalidomide, the first 12 participants will be in the dose escalation phase; with the subsequent 8 participants anticipated to receive dose expansion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility